AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
June 01 2022 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments and therapies for atrial fibrillation (Afib), left
atrial appendage (LAA) management and post-operative pain
management, announced the appointment of Deborah Yount as Chief
Human Resources Officer, effective today. Ms. Yount will have
responsibility for global Human Resources activities.
“We are excited to have Deborah joining us at AtriCure,” said
Michael Carrel, President and Chief Executive Officer. “She brings
an incredible amount of industry and human capital expertise as we
enter a period of accelerated growth. Our opportunities to address
the global Afib epidemic and help patients manage post-operative
pain are profound, and I’m looking forward to having Deborah’s
partnership in this leadership role, helping us live out our
mission.”
Ms. Yount has held leadership roles at Medtronic PLC since April
2007, most recently serving as Vice President of Global Human
Resources for the Cardiovascular portfolio of businesses, which
represents over $10 billion in annual revenue. She served as a key
executive and a member of the portfolio leadership team during her
tenure. Deborah’s expertise resides in the thoughtful management of
the intersection of organizational strategy, talent, and culture.
She has been at the forefront of cultivating broad talent
strategies, developing human capital plans, and furthering
inclusion, diversity, and equity initiatives. Prior to Medtronic,
Ms. Yount held executive and leadership positions at Sirific
Wireless Corporation, Texas Instruments, and Nelson Human Resource
Solutions.
“It is a privilege to be joining AtriCure at such an exciting
time in the company’s evolution,” said Ms. Yount. “There are so
many progressive catalysts for the business. Prioritizing our
robust and inclusive culture and mission-driven work is more
important than ever as we cultivate growth opportunities for our
employees and expand our diverse workforce."
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first medical
device to receive FDA approval for the treatment of persistent
Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System
products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure
that provides a lasting solution for long-standing persistent Afib
patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for
temporary ablation of peripheral nerves to block pain, providing
pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220601005064/en/
Valerie Storch-Willhaus Media Relations Vice President,
Corporate Marketing & Communications (612) 605-3311
vstorch-willhaus@atricure.com
Angie Wirick Investor Relations Chief Financial Officer (513)
755-5334 awirick@atricure.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024